

Propensity-matched comparison of early intensive and escalation treatment strategy in Finnish MS patients

*Hänninen K¹, Viitala M², Atula S³, Laakso SM³, Kuusisto H⁴, Soilu-Hänninen M¹.

¹Turku University Hospital Neurocenter and Department of Neurology, University of Turku, Turku, Finland, ²StellarQ Ltd., Turku, Finland, ³Neurocenter, Helsinki University Hospital, Helsinki, Finland and Department of Neurosciences, University of Helsinki, Helsinki, Finland ⁴Department of Neurology, Tampere University Hospital, Finland and Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.

*Main author

Conflicts of interest statement of the authors: S Atula has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Novartis, Merck and Roche. H Kuusisto has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Celgene, Genzyme, Novartis, Merck, Roche and Sanofi. M Soilu-Hänninen has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Celgene, Genzyme, Novartis, Merck, Roche, Sanofi and Teva. SM Laakso has received honoraria for lectures from Merck and congress expenses covered by Roche and Merck. K Hänninen and M Viitala have nothing to disclose.